Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
August 02, 2022 08:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new...
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022
July 29, 2022 09:15 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment...
Salarius Pharmaceuticals to Participate in BIO International Convention 2022
June 09, 2022 07:33 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new...
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
May 18, 2022 16:10 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
May 12, 2022 16:05 ET
|
Salarius Pharmaceuticals, Inc.
Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein degradation, and seclidemstat in protein...
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
May 11, 2022 16:05 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
May 05, 2022 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment...
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
April 22, 2022 08:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new...
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
March 10, 2022 16:05 ET
|
Salarius Pharmaceuticals, Inc.
Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies Clinical development of seclidemstat is continuing...
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
March 03, 2022 07:31 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new...